Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilta-cel in High-Risk Smoldering Multiple Myeloma
NCT06574126Phase 2Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2024
- Primary completion
- Sep 2032
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ciltacabtagene autoleucel in smoldering multiple myeloma (SMM), sponsored by Fundación PETHEMA. Started Sep 2024; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06574126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574126.